Osteosarcoma is the most common bone tumor and a highly aggressive malignant neoplasm. This study aims to elucidate the role of lactylation-related genes (LRGs) in osteosarcoma, with the goal of improving prognostic accuracy and enhancing the efficacy of immunotherapy. Using public datasets, we integrated differential and correlated genes based on single-cell sequencing AUCell scores and performed enrichment analysis and risk model construction on these genes. A total of 277 genes were found to be intricately linked with lactate metabolism. Using the uni-Cox and LASSO algorithm, nine key genes were identified, demonstrating strong predictive power for the prognosis of Osteosarcoma patients. Notably, changes were observed at the levels of immune checkpoints, the tumor microenvironment (TME), drug sensitivity, and immune cell infiltration. This study paves the way for targeted drug interventions, thereby opening avenues for improving clinical outcomes in osteosarcoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10142-025-01559-4 | DOI Listing |
Funct Integr Genomics
March 2025
Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Osteosarcoma is the most common bone tumor and a highly aggressive malignant neoplasm. This study aims to elucidate the role of lactylation-related genes (LRGs) in osteosarcoma, with the goal of improving prognostic accuracy and enhancing the efficacy of immunotherapy. Using public datasets, we integrated differential and correlated genes based on single-cell sequencing AUCell scores and performed enrichment analysis and risk model construction on these genes.
View Article and Find Full Text PDFNanomaterials (Basel)
February 2025
CNRS, Institut de Physique de Rennes (IPR), UMR 6251, Université de Rennes, 35000 Rennes, France.
Osteosarcoma is medically defined as a bone-forming tumor with associated bone-degrading activity. There is a lack of knowledge about the network that generates the overproduction of bone. We studied the early stage of osteosarcoma development with mice enduring a periosteum injection of osteosarcoma cells at the proximal third of the tibia.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
February 2025
Basaksehir Cam and Sakura City Hospital, Başakşehir, Istanbul, Turkey.
Difficult airway management in oromaxillofacial tumor surgery poses significant challenges for anesthesiologists. We present two case reports of patients with mandibular malignant tumors and maxillary osteosarcoma who underwent surgery under general anesthesia. Preoperative assessment revealed a mass involving the right mandible, completely covering the inside of the mouth and invading the floor of the mouth in the first case, and a mass in the left maxilla extending to the zygomatic arch and orbital floor in the second case.
View Article and Find Full Text PDFFront Pharmacol
February 2025
Department of East Hospital Orthopaedic Trauma, Zibo Central Hospital, Zibo, China.
Background: Osteosarcoma (OS) is the prevalent primary bone cancer, with a high proclivity for local invasion and metastasis. Previous studies have indicated that telomeres are closely related to prognosis of cancer, but the significance of telomere-related features in OS remains uncertain. Thus, the goal of this work is to identified telomere-related subtypes based on the telomere-related genes (TRGs).
View Article and Find Full Text PDFBull Cancer
March 2025
Department of Oncology for Child and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.
Osteosarcomas are radioresistant tumors whose first-line treatment is based on chemotherapy and surgery. To better define the role of radiotherapy, we carried out a review of the literature from the 2000s concerning children and adults. Radiotherapy can be offered post-operatively in cases of R1 resection, at a minimum dose of 60Gy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!